Alessandra Salerno

Alessandra Salerno

Auto-generated profile, based on publicly available information

Alessandra Salerno

Centre for Targeted Protein Degradation, School of Life Sciences University of Dundee 1 James Lindsay Place DD1 5JJ Dundee Scotland, U.K.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
CAClaudia Albertini
Claudia Albertini
ASAlessandra Salerno
Alessandra Salerno
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
MBMaria Laura Bolognesi
Maria Laura Bolognesi

8 April 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MRMichele Rossi
Michele Rossi
MFMichela Freschi
Michela Freschi
LNLuciana de Camargo Nascente
Luciana de Camargo Nascente
ASAlessandra Salerno
Alessandra Salerno
STSarah de Melo Viana Teixeira
Sarah de Melo Viana Teixeira
MBMaria Laura Bolognesi
Maria Laura Bolognesi
The multifactorial nature of Alzheimer’s disease (AD) is a reason for the lack of effective drugs as well as a basis for the development of “multi-target-directed ligands” (MTDLs). As cases increase in developing countries, there is a need of new drugs that are not only effective but also accessible. With this motivation, we report the first sustainable MTDLs, derived from cashew nutshell liquid (CNSL), an inexpensive food waste with anti-inflammatory properties. We applied a framework combination of functionalized CNSL components and well-established acetylcholinesterase (AChE)/butyrylcholinesterase (BChE) tacrine templates. MTDLs were selected based on hepatic, neuronal, and microglial cell toxicity. Enzymatic studies disclosed potent and selective AChE/BChE inhibitors (5, 6, and 12), with subnanomolar activities. The X-ray crystal structure of 5 complexed with BChE allowed rationalizing the observed activity (0.0352 nM). Investigation in BV-2 microglial cells revealed antineuroinflammatory and neuroprotective activities for 5 and 6 (already at 0.01 μM), confirming the design rationale.

11 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ASAlessandra Salerno
Alessandra Salerno
FSFrancesca Seghetti
Francesca Seghetti
JCJessica Caciolla
Jessica Caciolla
EUElisa Uliassi
Elisa Uliassi
ETEleonora Testi
Eleonora Testi
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this technology, a growing paradigm toward enriching PROTACs with other therapeutic modalities has been proposed. Could researchers successfully combine two modalities to yield multifunctional PROTACs with an expanded profile? In this Perspective, we try to answer this question. We discuss how this possibility encompasses different approaches, leading to multitarget PROTACs, light-controllable PROTACs, PROTAC conjugates, and macrocycle- and oligonucleotide-based PROTACs. This possibility promises to further enhance PROTAC efficacy and selectivity, minimize side effects, and hit undruggable targets. While PROTACs have reached the clinical investigation stage, additional steps must be taken toward the translational development of multifunctional PROTACs. A deeper and detailed understanding of the most critical challenges is required to fully exploit these opportunities and decisively enrich the PROTAC toolbox.

15 December 2022 in ACS Bio & Med Chem Au
Verified
Journal Article
Open access
RERocío Marisol Espinoza-Chávez
Rocío Marisol Espinoza-Chávez
ASAlessandra Salerno
Alessandra Salerno
ALAnastasia Liuzzi
Anastasia Liuzzi
AIAndrea Ilari
Andrea Ilari
AMAndrea Milelli
Andrea Milelli
MBMaria Laura Bolognesi
Maria Laura Bolognesi

10 April 2025 in Journal of the American Chemical Society
Verified
Journal Article
Open access
ASAlessandra Salerno
Alessandra Salerno
LWLianne H. E. Wieske
Lianne H. E. Wieske
CDClaudia J. Diehl
Claudia J. Diehl
ACAlessio Ciulli
Alessio Ciulli
Proteolysis Targeting Chimeras (PROTACs) are bifunctional molecules that induce ubiquitination and degradation of a target protein via recruitment to an E3 ligase. The linker influences many steps of the PROTAC mode of action, from cellular permeability to ternary complex formation and target degradation. Much interest has therefore been devoted to linker design to fine-tune molecular and mechanistic properties of PROTACs. In this study, we present FerroTACs, a novel PROTAC design strategy incorporating ferrocene as the linker chemotype. We exemplify the approach across three different PROTAC systems: VHL-VHL (homo-PROTACs), VHL-CRBN, and VHL-BETs. We find that ferrocene's unique organometallic structure, featuring freely rotating cyclopentadienyl rings around a central Fe(II) ion, acts as a molecular hinge enabling structural adjustment to the environment that results in properties alteration, i.e., chameleonicity. Conformational analyses via NMR spectroscopy support ferrocene's role in fostering intramolecular interactions that result in a more folded state in an apolar environment. This property promotes compact conformations, improving cellular permeability and reducing efflux liabilities. Cellular assays demonstrate that FerroTACs exhibit robust target degradation and cell permeability profiles, en-par or enhanced compared to benchmark PROTACs CM11, 14a, and MZ1. These findings highlight ferrocene's potential as a new linker design strategy, offering a versatile platform to install and control molecular chameleonicity into next-generation PROTACs.

22 July 2022 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
CAClaudia Albertini
Claudia Albertini
ASAlessandra Salerno
Alessandra Salerno
SASilvia Atzeni
Silvia Atzeni
EUElisa Uliassi
Elisa Uliassi
FMFrancesca Massenzio
Francesca Massenzio
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Polypharmacology is a new trend in amyotrophic lateral sclerosis (ALS) therapy and an effective way of addressing a multifactorial etiology involving excitotoxicity, mitochondrial dysfunction, oxidative stress, and microglial activation. Inspired by a reported clinical trial, we converted a riluzole (1)-rasagiline (2) combination into single-molecule multi-target-directed ligands. By a ligand-based approach, the highly structurally integrated hybrids 3-8 were designed and synthesized. Through a target- and phenotypic-based screening pipeline, we identified hit compound 6. It showed monoamine oxidase A (MAO-A) inhibitory activity (IC50 = 6.9 μM) rationalized by in silico studies as well as in vitro brain permeability. By using neuronal and non-neuronal cell models, including ALS-patient-derived cells, we disclosed for 6 a neuroprotective/neuroinflammatory profile similar to that of the parent compounds and their combination. Furthermore, the unexpected MAO inhibitory activity of 1 (IC50 = 8.7 μM) might add a piece to the puzzle of its anti-ALS molecular profile.